



<http://researchspace.auckland.ac.nz>

ResearchSpace@Auckland

Copyright Statement

The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand).

This thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use:

- Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person.
- Authors control the copyright of their thesis. You will recognise the author's right to be identified as the author of this thesis, and due acknowledgement will be made to the author where appropriate.
- You will obtain the author's permission before publishing any material from their thesis.

To request permissions please use the Feedback form on our webpage.

<http://researchspace.auckland.ac.nz/feedback>

General copyright and disclaimer

In addition to the above conditions, authors give their consent for the digital copy of their work to be used subject to the conditions specified on the Library Thesis Consent Form.

INTERFERON AND THE ANTIBODY RESPONSE.

R. J. BOOTH

Department of Cell Biology,
University of Auckland.

A thesis submitted in fulfilment
of the requirements for the
degree of Doctor of Philosophy
from the University of Auckland.

August, 1976.

UNIVERSITY OF AUCKLAND
LIBRARY
BIOLOGY
THESIS

76-268
cop. 2

Biology
Thesis

7	6	6	4	0	1	2	0	2	5	0	1
---	---	---	---	---	---	---	---	---	---	---	---

76-268

cop. 2

TABLE OF CONTENTS.

	<u>Page</u>
ACKNOWLEDGEMENTS.	1
SUMMARY.	2
ABBREVIATIONS.	5
<u>CHAPTER 1.</u> INTRODUCTION.	7
1.1 THE BEGINNINGS OF INTERFERON RESEARCH.	7
1.11 The Discovery of Interferons.	7
1.12 Characteristics of Interferons.	8
1.13 The Broadening Range of Interferon Activities.	9
1.2 INTERFERON INDUCTION.	10
1.21 Type I Induction: Class A Inducers (Viruses and nucleic acids).	11
1.22 Type I Induction: Class B Inducers.	13
1.22.1 Microorganisms.	13
1.22.2 High molecular weight inducers.	14
1.22.3 Low molecular weight inducers.	14
1.23 Type II Interferon Inducers (Immune Interferon).	15
1.23.1 Immune-specific induction.	15
1.23.2 Interferon induction by mitogens.	19
1.24 Mechanisms of Type I Interferon Induction.	21
1.24.1 Regulation of interferon production.	22
1.24.2 Hyporeactivity.	23
1.24.3 Priming and blocking.	24
1.3 ANTIVIRAL ACTION OF INTERFERONS.	25
1.31 General Considerations.	25
1.32 The Mechanism of Antiviral Action.	28

	<u>Page</u>
1.32.1 Translation of viral mRNA.	30
1.33 Interferons and Hormones.	31
1.4 OTHER BIOLOGICAL ACTIVITIES ASSOCIATED WITH INTERFERONS.	32
1.41 Effects of Interferon on Infectious Organisms other than Viruses.	32
1.42 Effect of Interferon on Cell Growth.	33
1.42.1 Normal cells.	33
1.42.2 Tumour cells.	34
1.43 The Effect of Interferon on Immune Reactions.	36
1.43.1 The reticuloendothelial system and phagocytosis.	36
1.43.2 Cell-mediated immune reactions.	37
1.43.3 Humoral immunity.	40
1.44 Summary of the Effects of Interferon.	42
1.5 INTERFERON AND OTHER DEFENCE MECHANISMS.	43
1.51 Patterns of Viral Disease.	43
1.52 Relative Importance of Various Defence Mechanisms.	44
1.52.1 Phagocytosis.	44
1.52.2 Cell-mediated immunity (CMI).	45
1.52.3 Humoral immunity.	49
1.52.4 Interferon.	51
1.53 Interactions Between Defence Mechanisms.	53
1.6 WORK DESCRIBED IN THIS THESIS.	56
<u>CHAPTER 2.</u> MATERIALS AND METHODS.	58
2.1 MATERIALS.	58
2.11 Chemicals.	58
2.12 Enzymes.	59
2.13 Viruses and Cells.	59

	<u>Page</u>
2.14 Interferon Standards.	60
2.15 Human Interferon.	60
2.2 MEDIA AND BUFFERED SOLUTIONS.	60
2.21 Dulbecco's Phosphate Buffered Saline (PBS) and Gel-saline.	60
2.22 0.01M Phosphate Buffer for Interferon Purification.	61
2.23 Puck's Saline.	61
2.24 Shortman's Balanced Salts Solution (SBSS).	62
2.25 Alsever's Solution.	62
2.26 L Cell Culture Medium.	63
2.27 Spleen Cell Culture Medium.	63
2.28 0.25% Trypsin Solution.	63
2.29 Plaque Assay Media.	64
2.29.1 Virus plaque assay agar overlay.	64
2.29.2 Antibody plaque assay medium.	64
2.3 CELL CULTURE TECHNIQUES.	65
2.31 Growth of L Cells.	65
2.31.1 Monolayer cultures.	65
2.31.2 Suspension cultures.	65
2.31.3 Trypsinisation of L cells.	65
2.32 Growth and Assay of Viruses.	65
2.32.1 Semliki Forest Virus.	65
2.32.2 Reovirus.	66
2.32.3 Semliki Forest Virus plaque assay.	66
2.32.4 Reovirus plaque assay.	66
2.33 Immunological Culture Techniques.	67
2.33.1 Preparation of spleen cells.	67
2.33.2 Preparation of thymus cells.	67
2.33.3 The primary antibody response in Marbrook culture vessels.	68

	<u>Page</u>
2.33.31 Antibody plaque assay.	68
2.33.4 The primary antibody response in polyacrylamide culture vessels.	69
2.33.41 Preparation of polyacrylamide culture vessels.	69
2.33.42 The polyacrylamide culture system.	69
2.33.43 The modified antibody plaque assay.	70
2.33.44 Statistical considerations.	70
2.33.45 The 'filler cell' population.	70
2.4 MISCELLANEOUS METHODS.	71
2.41 Glassware.	71
2.41.1 Siliconisation of glassware.	71
2.42 Sterilisation.	71
2.43 Calf Serum and Foetal Calf Serum.	71
2.44 Cell Viability Test.	72
2.44.1 Trypan blue dye exclusion.	72
2.44.2 Fluorescein diacetate uptake.	72
2.45 Scintillation Fluid.	72
2.46 Protein Determinations.	73
<u>CHAPTER 3.</u> PRODUCTION, PURIFICATION AND ASSAY OF INTERFERON.	74
3.1 INTRODUCTION.	74
3.2 METHODS AND RESULTS.	77
3.21 Assay of Interferon Preparations.	77
3.22 Induction of Interferon Production.	78
3.23 The Effect of Reovirus Multiplicity on Interferon Induction.	79
3.24 The Effect of Ageing Time on Interferon Induction.	79
3.25 Effect of Temperature on Interferon Production.	80

	<u>Page</u>
3.26 Purification of Interferon Preparations.	81
3.27 Control Supernatants.	81
3.3 DISCUSSION.	82
3.31 The Interferon Assay.	82
3.32 The Production of Interferon.	83
3.33 Concluding Remarks.	85
<u>CHAPTER 4.</u> THE EFFECT OF INTERFERON ON THE ANTIBODY RESPONSE <u>IN VITRO.</u>	 86
4.1 INTRODUCTION.	86
4.2 EXPERIMENTAL RESULTS.	87
4.21 The Effect of Interferon on the Antibody Response <u>in vitro.</u>	 87
4.22 Modulating Effects of Interferon Preparations.	87
4.23 Properties of the Inhibitory Substance.	88
4.24 Interferon and the Response of T and B Lymphocytes.	88
4.24.1 B lymphocytes.	89
4.24.2 T lymphocytes.	89
4.3 DISCUSSION.	90
4.31 The Effect of Interferon on the PFC Response and Cell Viability.	 90
4.32 The Enhancing and Suppressive Properties of Interferon Preparations.	 90
4.33 A Comparison of the Immunoregulatory and Antiviral Activities of Interferon Preparations.	 92
4.34 The Target Cell for Interferon.	94
4.35 Immunosuppression at Physiological Interferon Concentrations.	 95

	<u>Page</u>
<u>CHAPTER 5.</u> KINETICS OF INTERFERON-INDUCED ANTIBODY SUPPRESSION.	97
5.1 INTRODUCTION.	97
5.2 EXPERIMENTAL RESULTS.	98
5.21 Effect of Time of Addition of Interferon.	98
5.22 Effect of Limited Exposure of Cultures to Interferon.	98
5.23 Effect of Pretreatment with Interferon.	99
5.24 The Effect of Pretreatment Temperature on Interferon-induced Antibody Suppression.	99
5.25 The Effects of Absorption of Interferon Preparations with Spleen Cells.	100
5.26 The Effect of Interferon on the Time-course of the Antibody Response.	100
5.3 DISCUSSION.	101
5.31 The Time of Interferon Action.	101
5.32 Temperature-dependence of Interferon-induced Immunosuppression.	103
5.33 The Uptake of Interferon by Spleen Cells.	104
5.34 The Timing of the Suppressive Effect.	105
5.35 Heterogeneity of B Cell Precursors.	106
5.36 Interpretation of Detailed Time-course Studies.	107
5.37 Concluding Remarks.	107
<u>CHAPTER 6.</u> THE MECHANISM OF INTERFERON-INDUCED IMMUNOSUPPRESSION.	109
6.1 INTRODUCTION.	109
6.2 EXPERIMENTAL RESULTS.	110
6.21 Dose-response Curve.	110
6.22 Effect of Interferon on the Size and Number of Clones of Antibody-forming Cells.	110

	<u>Page</u>
6.23 The Effect of Interferon on the Kinetics of the Antibody Response.	111
6.3 DISCUSSION.	111
6.31 The Polyacrylamide Culture System.	111
6.32 The Effect of Interferon on Clones Observed at the Peak of the Response.	113
6.33 The Time-course of Interferon Suppression of PFC Clones.	113
6.34 The Mechanism of Immunosuppression by Interferon.	114
A. Previous Observations.	115
B. Observations Reported in this Chapter.	116
<u>CHAPTER 7.</u> CONCLUDING DISCUSSION.	117
7.1 THE RELATIONSHIP BETWEEN THE INTERFERON AND IMMUNE SYSTEMS.	117
7.2 TYPE I INTERFERON AND THE ANTIBODY RESPONSE.	118
7.3 CHARACTERISTICS OF INTERFERON-INDUCED ANTIBODY SUPPRESSION.	120
7.31 The Target Cell for Interferon.	120
7.32 The Time of Interferon Action.	121
7.33 The Interaction of Interferon with Spleen Cells.	122
7.34 The Time of the Interferon Effect.	123
7.4 INTERFERON-INDUCED SUPPRESSION OF CLONES OF ANTIBODY- FORMING CELLS.	124
7.41 The Doubling Time of Proliferating Clones of AFCs in Culture.	125
7.5 THE MECHANISM OF INTERFERON-INDUCED ANTIBODY SUPPRESSION.	126
7.6 INTERFERON AS A REGULATORY FACTOR IN ANTIBODY RESPONSES.	127
7.61 The Properties of Interferon which Conform to those Expected for an Immune Response Regulator.	127

	<u>Page</u>
7.62 Comparison Between Interferon and Other Lymphokines.	129
7.62.1 Interferon and MIF.	130
7.62.2 Interferon and SIRS.	130
7.7 IMPLICATIONS OF THE MECHANISM OF INTERFERON-INDUCED IMMUNOSUPPRESSION.	131
7.71 The Interferon and Antibody Responses During Viral Infections.	132
7.72 Immunosuppression as a Protective Mechanism During Viral Infections.	133
7.72.1 Protection against immunologically-mediated tissue damage.	135
7.72.2 Protection from virus-mediated destruction of lymphocytes.	136
7.72.3 Protection against tolerance induction.	137
7.72.31 Theories of tolerance induction.	138
(1) Tolerance via exhaustive immunisation.	139
(2) Two-signal model for immunisation.	139
(3) Antigen presentation model.	140
(4) Tolerogenesis of blast cells.	140
7.8 CONCLUDING REMARKS.	141
REFERENCES.	142
APPENDIX.	184

ACKNOWLEDGEMENTS.

I should like to express my gratitude to the Medical Research Council of New Zealand for its financial support in the form of a Postgraduate Scholarship; to Professor R.E.F. Matthews for use of the facilities of the Department of Cell Biology; to my supervisors, Dr. J. Marbrook and Associate-Professor A.R. Bellamy for stimulating discussions and assistance; to my wife Joan for her excellent technical assistance and continual encouragement; to my mother for typing the thesis; to all my family for their continued support and encouragement throughout.

SUMMARY.

- (1) The effect of mouse interferon on the primary in vitro antibody response of mouse spleen cells against sheep erythrocytes was studied. Concentrations of interferon greater than 8 units/ml significantly inhibited the antibody response while low concentrations of 0.08 - 0.8 units/ml were mildly enhancing. No effect on cell viability was observed with any of the interferon concentrations. The effects were specific for mouse interferon as human interferon had no effect on the antibody response of mouse spleen cells.
- (2) The immunosuppressive activity of crude and partially-purified interferon preparations correlated with the interferon titres. The antiviral and immunosuppressive activities of interferon preparations were equally sensitive to trypsin, heat and periodate treatments and insensitive to nuclease and low pH treatments. These results strongly indicated that both activities were functions of similar molecules with the properties of glycoproteins.
- (3) The polyclonal response of mouse spleen cells to the B cell mitogen lipopolysaccharide was suppressed by interferon while the proliferative response to the T cell mitogen phytohemagglutinin was unaffected.
- (4) Suppression was most marked when interferon was present from the beginning of the culture period. Addition of interferon at later times had progressively less inhibitory effect. Interferon had no effect when added after 48 hours.
- (5) Suppression of the antibody response was observed when spleen cells were pretreated for four hours at 37°C before antigenic challenge.

No suppression resulted following pretreatment at 4°C. No measurable quantity of interferon was taken up by the cells during pretreatment.

(6) Although interferon appeared to act during the first few hours of the antibody response no suppression of the early response was observed. The suppressive effect was not apparent for at least 50 hours. The kinetic data has been interpreted in terms of interferon-sensitive and interferon-resistant clones of antibody-forming cells.

(7) The presence of interferon-sensitive and interferon-resistant antibody-forming cell precursors was demonstrated using a culture system which permitted individual clones to be studied. Interferon had no effect on the division of B cells but suppressed the antigen-induced activation of some B cell precursors. The effect was an "all-or-nothing" phenomenon. Precursors which were suppressed by interferon were completely suppressed while interferon-resistant precursors were able to develop normally into clones of antibody-forming cells in the presence of interferon.

(8) A mechanism for interferon-induced antibody suppression has been proposed. Interferon only suppresses the activation of non-dividing B cell precursors. Once precursors have become activated and entered cell cycle they are refractory to suppression by interferon. This mechanism adequately explains all the observations.

(9) Three theories, which are not mutually exclusive, have been proposed to explain the significance of interferon-induced suppression of the antibody response during viral infections. These theories

suggest that suppression might function as a protective mechanism which operates at a time when an active antibody response would in some way be harmful to the host. The first theory concerns non-specific immunologically-mediated tissue damage which may result if antibody production was not suppressed by interferon during viral infections. The other two theories deal with conservation of the immune system. Interferon may either prevent virus-mediated destruction of activated lymphocytes or protect the immune system against the possible induction of specific tolerance to viral antigens.

ABBREVIATIONS.

AFC	antibody-forming cell
ALS	antilymphocyte serum
B cell	a cell of the antibody-forming cell lineage
BCG	Mycobacterium tuberculosis (strain BCG)
Ci	curie
CMI	cell-mediated immunity
con A	concanavalin A
CS	calf serum
CV	Chikungunya virus
Dimethyl POPOP	1,4-bis [2(4-methyl-5-phenyl-oxazolyl)] benzene
DNA	deoxyribonucleic acid
DTH	delayed-type hypersensitivity
EDTA	ethylenediamine tetraacetic acid
EMC	encephalomyocarditis
FCS	foetal calf serum
g	grammes or times gravity
GVH	graft-versus-host
HEPES	N-2-Hydroxyethylpiperazine-N'-2-ethanesulphonic acid
HSV	herpes simplex virus
JMM	Joklik-modified medium
Kg	kilogramme
LCM	lymphocytic choriomeningitis
LPS	lipopolysaccharide
<u>M</u>	molar
MEM	minimum essential medium
MIF	macrophage migration inhibition factor
mg	milligramme

ml	millilitre
mm	millimetre
m. o. i.	multiplicity of infection
mRNA	messenger RNA
NDV	Newcastle disease virus
nm	nanometer
PBS	phosphate-buffered saline
PFC	plaque-forming cell
PFU	plaque-forming unit
PHA	phytohemagglutinin
poly I:C	polyriboinosinic-polyribocytidilic acid
poly U	polyribouridylic acid
PPD	purified protein derivative from tuberculin
PPO	2,5-Diphenyloxazole
PWM	poke weed mitogen
RES	reticuloendothelial system
RNA	ribonucleic acid
SBSS	Shortman's balanced salts solution
SFV	Semliki forest virus
SIRS	soluble immune response suppressor
SRBC	sheep red blood cells
SV 40	simian virus 40
T cell	thymus-derived cell
TRIC	trachoma-inclusion conjunctivitis
tRNA	transfer RNA
μg	microgramme
μl	microlitre
UV	ultraviolet
VSV	vesicular stomatitis virus